RxDoctor Payments Data

Erin Sheehan

Psychiatric/Mental Health · Key West, FLNPI 1851644629

Payments from drug & device makers

$3,641in general payments, 2019–2025

Across 69 payments — averaging $52.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$746
  • Teva Pharmaceuticals USA, Inc.$513
  • Neurocrine Biosciences, Inc.$494
  • AbbVie$378
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$258
  • Idorsia Pharmaceuticals US Inc$249
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$3,641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,641 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$31,428
Medicare patients
122
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl24$69,150
RexultiBrexpiprazole12$16,446
Quetiapine Fumarate45$2,016
Bupropion XlBupropion Hcl56$1,732
Trazodone Hcl71$1,049
Duloxetine Hcl30$823
Lurasidone Hcl15$564
Lamotrigine28$492
Venlafaxine Hcl ErVenlafaxine Hcl12$398
Aripiprazole13$366
Donepezil Hcl23$288
Gabapentin18$287
Clonazepam30$230
Buspirone Hcl15$228
Escitalopram Oxalate19$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$378$69,15024 claims
Otsuka America Pharmaceutical, Inc.Rexulti$746$16,44612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Key West

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →